MedLife account plan
largest private medical network
At a glance
MedLife is Romania's largest private healthcare provider, with clinics, 18 hospitals and labs, and FY2025 revenue of RON 3,173,518,743 (+16.9%).
MedLife (Med Life S.A., founded 1996, Bucharest) is the largest private healthcare provider in Romania, running clinics, hospitals, laboratories, pharmacies, dentistry and corporate prevention packages, plus operations in Hungary and the Republic of Moldova. It has served over 6.5 million unique patients and has over 930,000 active corporate subscriptions; 51% of 2025 revenue came from individuals, 15% from corporations and 34% from the National Health Insurance House (NHIH). FY2025 IFRS revenue was RON 3,173,518,743 (+16.9%) and pro-forma adjusted EBITDA RON 459,728,962, but the group posted a net loss of RON 3,850,654 on higher financing costs. It works with over 5,200 doctors and over 4,600 nurses and medical staff, is listed on the Bucharest Stock Exchange (ticker "M") and is controlled by the Marcu family.
Business units
Clinics
37.3% of FY2025 sales (RON 1,184,308,228)Outpatient care and imaging through hyperclinics and smaller clinics, including the Neolife oncology group. Visits rose 12% in 2025 and revenue 15.8%; Clinics were 39% of sales in H1 2026 with revenue +15%.
Hospitals
27.8% of FY2025 sales (RON 883,256,613)Romania's largest private hospital network: 18 hospitals with 1,608 beds, including maternities and robotic surgery. Revenue grew 33.5% in 2025 as new capacity filled, then 8% in H1 2026 as growth normalised.
Laboratories
11.1% of FY2025 sales (RON 352,036,726)46 laboratories with over 250 collection points under the MedLife and Sfânta Maria brands, growing in molecular biology and genetics. Revenue rose 19.2% in 2025 and 13% in H1 2026; the Longevity100+ genomics program runs here.
Corporate
9.7% of FY2025 sales (RON 306,922,059)Prevention and occupational health packages sold to employers. Revenue rose 3.4% in 2025, then 17% in H1 2026 on subscriptions +12.5% to 999,018.
Dentistry
3.9% of FY2025 sales (RON 122,214,708)Fee-for-service dental care from check-ups to implants, the only line in decline (-2.6% in 2025, -4% in H1 2026); it is refocusing on medium- to high-end services.
Pharmacies
2.5% of FY2025 sales (RON 78,400,432)19 PharmaLife pharmacies inside or near hyperclinics and hospitals. Revenue rose 13.2% in 2025 and 34% in H1 2026.
Others
7.8% of FY2025 sales (RON 246,379,977)Pharmachem pharmaceutical distribution, the stem cell bank, the SanoPass fitness subscription platform and Sweat Concept centers. Revenue fell to RON 109,833,899 in H1 2026 on lower wholesale distribution.
Strategic priorities
- Regional expansion
- On 21 October 2026 MedLife set the direction of accelerating expansion across Central and Eastern Europe with priority on the Balkans, via acquisitions, greenfields or partnerships and a regional investment platform with an international financial institution.
- Genomics and AI
- Scale the Longevity100+ genetic testing program, add microbiome analysis, and accelerate AI in imaging and laboratories; a new app combining biometrics, lab results, imaging and genome data is opening to all users.
- Profitability of recent projects
- After an intensive investment cycle, the main 2026 priority is to maximise profitability of organic projects; the 2026 EBITDA budget is RON 512 million.
- Deleveraging
- Net debt to pro forma EBITDA was 3.85x at end-June 2026, with a target of around 3.5x by end-2026; new debt will be in local currency.
- Small and medium acquisitions
- M&A focuses on small and medium-sized deals in Romania and the region, including aesthetics, sports and wellness; Qualipat (75%) was bought in August 2026.
Latest results
In H1 2026 IFRS revenue was RON 1,738,986,990 against RON 1,573,957,005 in H1 2025, with pro-forma sales up almost 11% and organic growth of 9.5%. Pro forma EBITDA rose 14.5% to 259m RON, a 16.4% margin, and operating profit edged up 2.3% to RON 86,257,266. The net result was a loss of RON 34,689,177, as the RON's fall against the EUR raised FX losses on euro borrowings. Management says the group is on track with its budget and plans no price increases, with volume growth offsetting a slightly lower ticket.
Investments and deals
- Capital increase and regional platform
- MedLife is considering issuing new shares of up to 20% of share capital over up to 18 months, and a platform investing in healthcare, prevention and wellness companies over a four-year horizon, with first investments expected in the first half of next year.
- Acquisitions 2025-2026
- Routine Med (Tulcea), All Clinic (Republic of Moldova), Medstar (Cluj-Napoca, completed January 29, 2026) and 75% of Qualipat (pathology and molecular testing, August 2026).
- New facilities
- A Pitești hyperclinic (over EUR 3 million), the Panduri hyperclinic in Bucharest (over EUR 1 million), a fourth Arad clinic with a Longevity Center and a Neolife oncology center in Bacău.
- Robotic surgery and capex
- Over 2 million Euro invested in robotic surgery at Polisano Sibiu; the 2026 CAPEX budget is EUR 20 million excluding acquisitions.
Challenges and risks
- Currency exposure on euro debt
- Interest-bearing debt was RON 2,023,753,968 at June 30, 2026, mostly in EUR; the RON's fall cost RON 56 million in the Q2 2026 financial result.
- Slowing consumer spending
- Consumption in Romania has been falling since October 2025 after tax increases, pressuring discretionary services such as dentistry.
- State contracts for new hospitals
- Two new hospitals still await National Health Insurance House contracts; one is EBITDA positive, the other slightly negative.
- Clinical staff
- Recruitment and retention of staff, wage inflation for clinical staff and emigration of doctors are stated risks.
- Acquisition integration
- Due diligence and post-acquisition integration are named risks for a group that has integrated over 100 companies.
What leadership says
“We are no longer just talking about treatment, but about anticipation.”
“We are not currently looking at any large deals”
“We remain attentive to consolidation opportunities across the region and believe that MedLife's expertise represents a significant competitive advantage in this process.”
“We don't currently see any sizeable transactions materializing in the near term”
Where a supplier can help
- AI for imaging and laboratories
- Tied to the genomics and AI priority: AI imaging, lab automation and data tools fit MedLife's plan to accelerate AI in imaging and laboratories.
- Hospital margin improvement
- Tied to maximising profitability of recent organic projects: procurement, consumables and operational efficiency offers address a group whose consumables rose 27.0% in 2025.
- Treasury and FX advisory
- Tied to the euro debt exposure and the deleveraging target: local-currency financing, hedging and capital-markets advice fit the FX rebalancing under way.
- Integration of acquired clinics
- Tied to regional expansion and integration risk: IT, HR and finance integration services support a group buying companies in Romania and the Balkans.
- Clinical recruiting
- Tied to the staff retention risk: recruiting and retention services for doctors and nurses address a stated pressure.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like MedLife?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- MedLife Group 2025 Annual Report (consolidated)
- MedLife is Romania's largest private healthcare provider, listed on the Bucharest Stock Exchange (Premium category, ticker "M") since December 2016; it served over 6.5 million unique patients and has over 930,000 active corporate medical subscriptions.
- FY2025 IFRS revenue was RON 3,173,518,743, up 16.9%; operating profit rose 13.2% to RON 158,994,730, but the group posted a net loss of RON 3,850,654 (profit of RON 16,752,427 in 2024) as the financial result worsened 38% on higher debt and RON depreciation against the euro.
- Pro-forma adjusted EBITDA rose 16.4% to RON 459,728,962; the chairman's letter says revenue passed the EUR 600 million threshold and market capitalisation reached EUR 1 billion (shares up 77% in 2025).
- Six business lines: Clinics 37.3% of sales, Hospitals 27.8% (fastest growing, +33.5%), Laboratories 11.1%, Corporate 9.7%, Dentistry 3.9% (the only line in decline, -2.6%), Pharmacies 2.5%, plus Others 7.8%.
- Payer mix: 51% of revenue from individuals, 15% from corporations, 34% from patients insured by the National Health Insurance House (NHIH).
- Network at end-2025: 36 hyperclinics, 80 clinics, 18 hospitals with 1,608 beds, 4 maternities, 46 laboratories with over 250 collection points, 19 pharmacies, 17 dental clinics, plus Hungary (3 facilities) and the Republic of Moldova (3 centers); over 5,200 doctors and over 4,600 nurses and medical staff.
- 2025 deals: Routine Med (Tulcea), All Clinic (Moldova, second foreign market after Hungary), Medstar (Cluj-Napoca, completed in early 2026); over 100 companies acquired and integrated between 2010 and end-2025.
- 2026 priorities: scale the Longevity100+ genetic testing program, AI in imaging and labs, maximise profitability of recent organic projects, prudent acquisitions incl. aesthetics, sports and wellness, and careful evaluation of regional markets.
- Interest-bearing debt rose 14.6% to RON 1,931,339,625, mostly EUR-denominated syndicated loans maturing 2031; no dividends are proposed while growth stays in line with historical trends.
- MedLife Group financial report for the six-month period ended June 30, 2026 (H1 2026, IFRS consolidated)
- H1 2026 IFRS revenue was RON 1,738,986,990 (RON 1,573,957,005 in H1 2025); pro forma gross sales RON 1,741,998,742 and pro forma adjusted EBITDA RON 258,894,525.
- Operating profit edged up 2.3% to RON 86,257,266, but the net result was a loss of RON 34,689,177 (loss of RON 10,885,945 a year earlier), as the RON's fall against the EUR raised FX losses on euro borrowings.
- By business line: Clinics RON 674,992,716 (visits 2,662,268), Hospitals RON 473,904,667 (109,202 patients), Laboratories RON 194,559,115, Corporate RON 175,640,933 with 999,018 subscriptions, Dentistry RON 59,593,514 (lower), Pharmacies RON 50,462,145, Others RON 109,833,899 (lower).
- Network: 37 hyperclinics, 94 clinics, 18 hospitals, 4 maternities, 47 laboratories, 19 pharmacies, 17 dental clinics and 300 partner clinics.
- Medstar (Cluj-Napoca) completed on January 29, 2026; new Panduri hyperclinic in Bucharest (over EUR 1 million) and a fourth Arad clinic with a Longevity Center.
- Longevity100+ genomics study published first results and added microbiome analysis.
- Interest-bearing debt rose 5% to RON 2,023,753,968; operating cash flow RON 141,212,289; PP&E purchases RON 79,432,122.
- After the period: 75% of Qualipat (anatomical pathology and molecular testing, Timișoara and Oradea, about EUR 1.2 million turnover in 2025).
- MedLife H1 2026 results conference call transcript
- H1 2026 pro-forma sales reached RON 1.7 billion, up almost 11%, with organic growth of 9.5%; pro forma EBITDA rose 14.5% to 259m RON, a 16.4% margin (13.9% on IFRS).
- An RON depreciation of about 2.8% against the EUR in Q2 cost RON 56 million in the financial result, leading to a pro-forma net loss of RON 20.4m.
- Corporate (+17% revenue, subscriptions +12.5%) and Clinics (+15%, 39% of sales) led; Laboratories +13%, Hospitals +8%, Dentistry -4%, Pharmacies +34%.
- Net debt to pro forma EBITDA stood at 3.85x; target remains around 3.5x by end-2026.
- FX plan: any new debt will be in local currency; EUR-denominated corporate contracts act as a natural hedge; swaps are being studied; Marcu did not exclude a capital increase.
- M&A: small and medium-sized deals only, in Romania and the region; "We are not currently looking at any large deals". Qualipat (75%) bought in August.
- Marcu confirmed the RON 512 million 2026 EBITDA budget as achievable and said no price increases are planned, as volume growth offsets a slightly lower ticket.
- Two new hospitals still await National Health Insurance House contracts; one is EBITDA positive, the other slightly negative.
- Product push: microbiome sequencing in-house, genome, and a new app (MedLife/iMed) combining biometrics, lab results, imaging and genome data.
- MedLife Q1 2026 results conference call transcript
- Q1 2026 consolidated pro forma turnover was RON 856.2 million, up 10.1%, of which 9% organic; pro forma EBITDA rose 10% to RON 124.3 million (16% margin pro forma, 14% IFRS); pro forma net result RON 12.6 million.
- Clinics 39% of sales with visits +10.4%; Hospitals revenue +11%; Laboratories +11%; Corporate revenue +11.6% on subscriptions +7.2%; Dentistry -2.7%; Pharmacies +30.5%.
- Consumer spending in Romania has been falling since October 2025; the ticket per patient is slightly lower, offset by volume.
- Net debt to pro forma EBITDA 3.85x; target 3.5x by end-2026; 2026 CAPEX budget EUR 20 million excluding acquisitions.
- Prices were raised in Q1 (clinics 5%, hospitals 5% to 10%, laboratories 3%); no further increases planned.
- Timișoara hospital broke even in Q4 2025 and NORD hospital early 2026; neither has a National Health House contract yet.
- Hedging was judged too expensive; future facilities may be RON-denominated.
- No sizeable M&A expected near term; priorities are genetics (Longevity100+), the new app and Corporate products.
- Lecții pentru 2026 – Mihai Marcu (MedLife) (Forbes Romania)
- Short Q&A for Forbes Romania's "Lessons for 2026" series (answers dated 25 November 2025, published 9 January 2026), in Romanian; quotes below are translations.
- Marcu's word for 2025 was "Innovation"; he says progress is no longer optional but "a condition of survival" (translated).
- Main worry: political instability; taxes rose and MedLife was directly hit by 3-4 of them; consumption is slowing.
- Healthcare is more resilient than other sectors: people can postpone a car or holiday but not health, so he sees a slowdown in growth, not a decline.
- 2025 results were good, in line with or above some estimates, but the context remains hard to predict.
- 2026 strategy: accelerate AI integration, especially in imaging and laboratory; expand genomics projects; consolidate MedLife as leader in medical innovation, including by expanding infrastructure.
- He asks the state to cut public spending and streamline the budget apparatus; urges faster absorption of EU funds.
- MedLife explores the potential use of new instruments to support growth in Romania and across Central and Southeastern Europe (press release)
- On 21 October 2026 MedLife said it is considering two initiatives for its next growth phase: a share capital increase and a regional investment platform with a leading international financial institution.
- The capital increase would let the company issue new shares of up to 20% of share capital over up to 18 months, if market conditions and opportunities warrant, subject to shareholder approval.
- Uses: organic development projects, investments in medical infrastructure and market consolidation transactions.
- The board-approved direction is to accelerate expansion across Central and Eastern Europe with priority on the Balkans, building on Romania, Hungary and the Republic of Moldova, via acquisitions, greenfields or partnerships.
- The platform would invest in healthcare, prevention and wellness companies over a four-year horizon; first investments are expected in the first half of next year.
- MedLife cites average annual growth of more than 20% over the past 10 years and aims to keep a balanced debt profile.
- CEO Mihai Marcu wants to turn the Romanian, Hungarian and Moldovan experience into "a consolidation model" for Central and Southeastern Europe.
Questions about MedLife
What does MedLife do?
MedLife runs Romania's largest private healthcare network: clinics, hospitals, laboratories, pharmacies, dentistry and corporate prevention packages, plus facilities in Hungary and the Republic of Moldova.
What is MedLife's revenue?
FY2025 IFRS revenue was RON 3,173,518,743, up 16.9%. H1 2026 revenue was RON 1,738,986,990.
How many people work at MedLife?
MedLife works with over 5,200 doctors, over 4,600 nurses and medical staff and over 2,500 administrative staff, and cites over 12,000 employees and collaborators.
Who leads MedLife?
Mihai Marcu is Chairman and CEO; Dorin Preda is Deputy CEO and Alina Irinoiu-Titu CFO.
What is MedLife's strategy?
MedLife combines organic growth and acquisitions in Romania with expansion across Central and Eastern Europe, prioritising the Balkans, while developing genomics, AI and prevention.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)